Trial Profile
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2022
Price :
$35
*
At a glance
- Drugs Rocapuldencel T (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics
- 20 Jul 2020 Planned initiation date changed from 1 Feb 2016 to 1 Mar 2016.
- 20 Jul 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 07 Mar 2018 The recruitment status of this study is unknown because trial information has not been verified since 25 March 2016.